SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

A quarterly earnings beat, raised outlook and record AI-compute backlogalongside managements emphasis on customer prepayments and contract-backed financingsparked an after-hours rebound and widespread short-squeeze chatter. Bulls see strong demand and improved financing prospects, while skeptics remain concerned about heavy debt, interest costs, capital spending and the path to sustained cash flow.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is centered on governance and national-security concerns surrounding CEO Jensen Huangs relationship with a customer suspected of ties to Chinese intelligence, with traders debating whether the investigation and China chip-export questions could threaten his leadership or the business. Others see the drop as an overreaction and are buying the dip, while looking to the upcoming earnings report for a business-focused counterpoint.

Autonomi (ANT) is a cryptocurrency launched in 2025and operates on the Arbitrum platform. Autonomi has a current supply of 1,200,000,000 with 346,011,579 in circulation. The last known price of Autonomi is 0.03102024 USD and is up 12.83 over the last 24 hours. It is currently trading on 15 active market(s) with $148,822.58 traded over the last 24 hours. More information can be found at https://autonomi.com.

Aragon

Attention is heavily muddied by Anthropic IPO chatter mistakenly tagged to Aragons ANT token. The Aragon-specific discussion centers on the projects dissolution and completed token-redemption initiative, with holders unsure about conversion or exchange availability; other posts are mostly speculative trading reactions.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and conference call are driving attention, with traders debating the shift to recurring Samsung and Micron licensing revenue and the stronger balance sheet against an apparent estimates miss caused partly by amortizing Samsungs upfront fee over the agreement term. Bullish traders point to higher expected Q4 revenue, while skeptics cite lower product sales and the lack of a confirmed SK Hynix deal or Nasdaq uplisting.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNavs Q3 earnings report and conference call are driving immediate discussion, with traders noting an EPS beat but reacting to the share-price decline and debating whether the call offered meaningful progress. Many see the pending FCC rulemaking on the companys spectrum as the more important catalyst, while the bullish SpaceX-related thesis remains speculative and others point to regulatory delays and downside risk.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

INFQ is drawing attention ahead of its quarterly report, with traders looking for revenue, guidance and commercialization updates that could set it apart from other quantum companies. Optimism about its products and technical progress is countered by concerns over weak price action and volatility alongside the broader quantum and tech sectors.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zetas strong quarterly earnings beat and raised guidance have driven attention, with traders citing accelerating growth, improving profitability and analyst upgrades as support for the rally. The reaction is split between bulls expecting momentum to continue and skeptics focused on volatile post-earnings trading and resistance near recent levels.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos weaker-than-expected quarterly update and narrowed production outlook, amid Cigar Lake operating setbacks, are driving a sharp selloff and bearish discussion about further downside. Some traders see the decline as an opportunity, arguing that firm uranium-market fundamentals and longer-term nuclear demand remain intact.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs quarterly resultsstrong revenue and backlog growth but a wider-than-expected loss and Neutrons first launch pushed to 2027are driving the discussion. Traders are split between viewing the demand and backlog as evidence of growth and worrying about execution delays, ongoing losses, and dilution; shares have rebounded after the initial post-earnings selloff.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Anthropics new Claude workplace tools, including a spreadsheet product positioned against Excel, have raised concerns that Microsofts Office and Copilot franchises face stronger competition. Traders debate whether the threat is material or overstated given Microsofts entrenched enterprise ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's How Much $1000 Invested In Ligand Pharmaceuticals 20 Years Ago Would Be Worth Today

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 20 years by 12.04% on an annualized basis producing an average annual return of 20.96%. Currently, Ligand Pharmaceuticals has a marketread more...

Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call

On Thursday, Ligand Pharmaceuticals (NASDAQ:LGND) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
Benzinga APIs provide real-time access to earnings callread more...

Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy

(RTTNews) - Thursday, Ligand Pharmaceuticals Inc. (LGND) announced a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company, for upto $47 million, helping advance the latter's pipeline, which includes AVC-201 for the treatment of relapsed/refr...

Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare PartnersPR NewswireSAN DIEGO, Sept. 22, 2026 SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a...

Here's How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 15.5% on an annualized basis producing an average annual return of 27.11%. Currently, Ligand Pharmaceuticals has a marketread more...

These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?

Equity

Orchestra BioMed received an upgrade from BTIG while LifeStance Health Group received a price target hike from Barclays.

If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals has a marketread more...

$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand Pharmaceuticals has a marketread more...

Ligand Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $301.78, changing hands for $303.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $271.00, changing hands for $274.88/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

• Reported GAAP EPS of $2.67 down -13.59% YoY
• Reported revenue of $78.75M down -9.37% YoY
• Ligand raised 2026 adjusted earnings per diluted share guidance to approximately $9.50 to $9.75 from approximately $9.00 to $9.50, and reaffirmed total revenue guidance of $270M to $310M.

Ligands total revenues and income decreased 32% year-over-year, adjusted net income decreased 10%, and its single source Captisol supplier may result in delays or inability to meet partner demand.

Ligands royalty revenue rose 51% year-over-year to $70.3M; the XOMA acquisition more than doubled its portfolio to over 200 assets, while Ryjunea added royalty rights in Europe, the Middle East and Africa.

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Neutral Sentiment

<ul class="summary-bullets"><li>BTIG turned “more constructive” on OBIO after management indicated the Backbeat trial remains on track to complete enrollment.</li><li>The trial is testing a therapy in patients with uncontrolled high blood pressure who need a pacemaker.</li><li>Barclays said LFST shareholders’ offering helps reduce the overhang from private equity ownership.</li></ul>Orchestra BioMed (OBIO) and LifeStance Health Group (LFST) were in focus on Thursday, with the stocks breaching their 52-week highs as Wall Street turned more positive on both healthcare stocks.Analysts cited progress toward a key clinical milestone at Orchestra and a reduction in LifeStance’s private-equity ownership overhang.At the time of writing, <a href="https://stocktwits.com/symbol/LFST">LFST shares</a> were up more than 4% and trading at the levels last seen in November 2021, while <a href="https://stocktwits.com/symbol/OBIO">OBIO shares</a> surged 11% to their highest levels since February 2025.<h2 class="st-heading-2">BTIG Sees Over 40% Potential Upside In OBIO</h2>Orchestra BioMed received an upgrade from BTIG on Thursday as the medical-device company approaches a key milestone for its late-stage hypertension study.BTIG analyst Marie Thibault upgraded Orchestra to ‘Buy’ from ‘Neutral’ with a $10 price target, representing more than 40% upside from current levels. The firm said it has become “more constructive” after management indicated the Backbeat trial remains on track to complete enrollment around the end of the third quarter.The trial, being conducted in partnership with Medtronic (MDT), is testing a therapy in patients with uncontrolled high blood pressure who need a pacemaker. Orchestra is targeting to enroll 284 patients, with primary results expected in the second quarter of 2027.BTIG said Orchestra has now met several conditions it previously required before upgrading the stock, including staying on schedule and securing non-dilutive funding.The company received <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-receives-20-million-payment-medtronic-under">$35 million</a> in strategic capital earlier this year, including $20 million from Medtronic and <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-receives-15-million-investment-ligand-under?">$15 million</a> from Ligand&nbsp;Pharmaceuticals (LGND).&nbsp;Orchestra ended June with $110 million in cash and investments, which it <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-reports-second-quarter-2026-financial-results">expects</a> will fund operations into the fourth quarter of 2027.Retail sentiment surrounding OBIO on Stockwits turned ‘bullish’ from ‘bearish.’ The stock has gained around 40% so far this year.<h2 class="st-heading-2">Barclays Says LFST Stock Offering Reduces Private Equity Ownership Overhang</h2>LifeStance Health Group received a price target hike from Barclays on Thursday, a day after existing shareholders launched a secondary share offering.Barclays raised its price target on LifeStance to $15 from $13 and maintained an ‘Overweight’ rating, according to The Fly. This represents a 13% upside from current levels.On Wednesday, selling shareholders priced an offering of 22.25 million LifeStance shares at $12.35 per share, valuing the transaction at approximately $275 million. The offering price was at a 3.5% discount to the stock’s closing price of $12.80 on Tuesday.Barclays said the offering helps reduce the overhang from private equity ownership and added that LifeStance continues to execute well.Notably, LifeStance is not selling shares in the offering and will not receive any proceeds, which will instead go to the selling shareholders.Retail sentiment surrounding LFST on Stockwits turned ‘bullish’ from ‘neutral.’ The stock has surged 88% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/compass-ceo-robert-reffkin-says-upcoming-open-ai-anthropic-ip-os-are-already-boosting-luxury-housing-beyond-san-francisco/cZta1LyRJ6B">Compass CEO Robert Reffkin Says Upcoming OpenAI, Anthropic IPOs Are Already Boosting Luxury Housing Beyond San Francisco</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stock. (Photo Courtesy of Flavio Coelho via Getty Images)

LifeStance Health Group Inc

Medtronic Plc

Orchestra BioMed Holdings Inc

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Feed

News

Sentiment

Earnings

Fundamentals

Info

LGND News